Safinamide mesylate CAS 202825-46-5

$1 - 100 /Gram

Min. Order:

1 Gram

Contact Now

Product Description

Overview

Packaging & Delivery

Selling Units:: Gram

On March 22, 2017, the FDA approved the sale of Safinamide, the monoamine oxidase B inhibitor of Zabon and Newron, Italy. This is also the first new chemical entity (NCE) approved for the treatment of Parkinson’s disease in the United States in more than 10 years. ), used to prolong the efficacy of levodopa. Safinamide is a third-generation MAO-B inhibitor that can reduce the degradation of secreted dopamine and help maintain the concentration of dopamine in the brain. In addition, safinamide can also block voltage-dependent sodium channels on neurons, thereby inhibiting the release of glutamate. Therefore, safinamide has become a novel treatment for Parkinson's disease with both dopaminergic and non-dopaminergic mechanisms. Compared with the first and second generation MAO-B inhibitors, safinamide has higher selectivity for MAO-B, and its inhibitory effect on monoamine oxidase is reversible. The physiological activity of MAO-B can be completely after 8 hours of stopping the drug. recover.

Product Categories : API Intermediates > Safinamide Mesylate Intermediate

Hot Products

Email to this supplier

*Subject:
*To:

Ms. Lily
*Email:
*Message:

Your message must be between 20-8000 characters